Area of research
Otorhinolaryngology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Head and Neck Cancer Studies, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, and Lung Cancer Research Studies.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer
Abstract 2471: Interpretable HPV detection in head and neck cancer using foundation models and synthetic digital pathology
Corrigendum to “Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas”. [Oral Oncol. 163 (2025) 107207]
Non–Small Cell Lung Cancer, Version 4.2024
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV<sup>+</sup> Oropharyngeal Cancer
Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer
A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.
Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.
Oncologic Safety of Close Margins in Patients With Low- to Intermediate-Grade Major Salivary Gland Carcinoma
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience
CMET-06. AN ANALYSIS OF RESPONSE ENDPOINTS FOR BRAIN METASTASIS PATIENTS TREATED WITH STEREOTACTIC RADIOSURGERY AND PD(L)-1 INHIBITORS